KW&]I@+X]DG*_ZI2;[YK^~Z!M${FP*36)%;&
SYSTEM PROCESSING...
KW&]I@+X]DG*_ZI2;[YK^~Z!M${FP*36)%;&
SYSTEM PROCESSING...
Posted: 2025-05-01 22:44:35 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-05-01 22:45:00 UTC
Verified By
Rollup News
Immunotherapy has transformed the treatment of mismatch repair-deficient colorectal cancer by targeting neoantigens that accumulate in tumors, making them 'immune hot' and attracting T cells. Immunotherapy can eradicate tumors in some patients, avoiding the need for surgery. In metastatic disease, immunotherapy is more effective than chemotherapy, although some patients may experience early progression. Doublet immunotherapy can overcome this early progression but may cause more side effects. Immunotherapy can also cause autoimmunity, and some patients do not respond to it, necessitating ongoing research to improve its effectiveness.
Immunotherapy's effectiveness in mismatch repair-deficient colorectal cancer
The role of neoantigens in attracting T cells
Eradication of tumors with immunotherapy, avoiding surgery
Superiority of immunotherapy over chemotherapy in metastatic disease
Challenges of immunotherapy, including autoimmunity and non-response
Early progression in some patients treated with single-agent immunotherapy
Autoimmunity caused by immunotherapy
Non-response to immunotherapy in some patients